Lanean...
Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
AIMS: Large‐scale clinical trials have demonstrated clinical benefits of sacubitril–valsartan in symptomatic heart failure with reduced ejection fraction patients (PARADIGM‐HF), with potential benefits in patients hospitalized for acute decompensated heart failure (ADHF) (PIONEER‐HF) and fewer benef...
Gorde:
| Argitaratua izan da: | ESC Heart Fail |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley and Sons Inc.
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7261587/ https://ncbi.nlm.nih.gov/pubmed/32167679 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12676 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|